- Home
- RMCO vs IBIO Comparison
RMCO vs IBIO Comparison
Compare RMCO & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMCO
- IBIO
- Stock Information
- Founded
- RMCO 2021
- IBIO 2008
- Country
- RMCO United States
- IBIO United States
- Employees
- RMCO N/A
- IBIO N/A
- Industry
- RMCO Multi-Sector Companies
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- RMCO Miscellaneous
- IBIO Health Care
- Exchange
- RMCO Nasdaq
- IBIO Nasdaq
- Market Cap
- RMCO 14.9M
- IBIO 15.9M
- IPO Year
- RMCO N/A
- IBIO N/A
- Fundamental
- Price
- RMCO $1.25
- IBIO $0.71
- Analyst Decision
- RMCO
- IBIO Strong Buy
- Analyst Count
- RMCO 0
- IBIO 3
- Target Price
- RMCO N/A
- IBIO $4.87
- AVG Volume (30 Days)
- RMCO 18.6K
- IBIO 5.3M
- Earning Date
- RMCO 08-14-2025
- IBIO 05-02-2025
- Dividend Yield
- RMCO N/A
- IBIO N/A
- EPS Growth
- RMCO N/A
- IBIO N/A
- EPS
- RMCO N/A
- IBIO N/A
- Revenue
- RMCO $1,568,212.00
- IBIO $375,000.00
- Revenue This Year
- RMCO N/A
- IBIO $36.00
- Revenue Next Year
- RMCO N/A
- IBIO N/A
- P/E Ratio
- RMCO N/A
- IBIO N/A
- Revenue Growth
- RMCO 204.08
- IBIO 650.00
- 52 Week Low
- RMCO $0.74
- IBIO $0.64
- 52 Week High
- RMCO $1.32
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- RMCO 62.27
- IBIO 37.70
- Support Level
- RMCO $1.19
- IBIO $0.68
- Resistance Level
- RMCO $1.30
- IBIO $1.04
- Average True Range (ATR)
- RMCO 0.06
- IBIO 0.12
- MACD
- RMCO 0.02
- IBIO -0.00
- Stochastic Oscillator
- RMCO 80.00
- IBIO 7.89
About RMCO Royalty Management Holding Corporation
Royalty Management Holding Corp formed to invest or purchase assets that have current or near-term income to provide the company with accretive cash flow from which it can reinvest in new assets or expand cash flow from existing assets. These assets typically are natural resources assets (including real estate and mining permits), patents, intellectual property, and emerging technologies.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.